Q3 2020 Sales Performance

Vaccines Q3 2020 Sales All figures £m gsk Operating margin -500bps CER -610bps AER Sales Pandemic environment impact + Flu sales execution -9% CER -12% AER 2,308 50.3% 371 2,032 44.2% 445 535 374 371 1,162 363 899 1,031 850 Q319 Q320 Q319 Q320 Flu Meningitis Shingrix Established Operating profit Operating leverage from pandemic- related sales decline Key brand investment 90

View entire presentation